Treatment patterns and outcomes with second-line therapies in patients with advanced urothelial carcinoma previously treated with first-line enfortumab vedotin with pembrolizumab
{{output}}
Enfortumab vedotin with pembrolizumab (EV + pembro) has transformed first-line treatment of advanced urothelial carcinoma (aUC). No prospective data are available evaluating outcomes of different therapies following progression on EV + pembro. Patients who rec... ...
